During a live event, Jack Khouri, MD, discussed options for patients with multiple myeloma after relapse and choices to ...

Multiple myeloma (MM) is an incurable and biologically diverse blood cancer that begins with the uncontrolled growth of plasma cells in the bone marrow. One of plasma’s main roles is to produce ...

Despite being the second most common haematologic cancer globally, treatment options for multiple myeloma remain limited, with a significant need for new therapies. 1 Multiple myeloma originates i ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed ...

GSK's BCMA-directed antibody-drug conjugate Blenrep reduced the risk of death by 42% in a multiple myeloma trial that the company believes could be practice-changing. The DREAMM-7 study showed ...

Search for other works by this author on: ...

Gut microbiome analysis of patients with multiple myeloma receiving idecabtagene vicleucel (ide-cel) therapy revealed specific bacterial species linked to treatment response and toxicity outcomes.

Recent findings indicate that annual low-dose whole-body computed tomography (WBLDCT) significantly contributes to the management of smoldering multiple myeloma (SMM). A study published in the Journal ...

GSK’s Blenrep combos are being reviewed in 14 nations. Credit: Magda Wygralak/Shutterstock. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised GSK’s Blenrep for ...

Search for other works by this author on: ...

[Efficacy of CD19 Chimeric Antigen Receptors T Cells in the Treatment of Relapsed Patients with B Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation ...